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In several human and animal studies, medium-chain triglycerides decreased food intake more than did long-chain triglycerides. It is possible
that faster uptake and metabolism of medium-chain fatty acids in the liver is responsible for this difference. To test this hypothesis we compared
the feeding effects of hepatic portal vein (HPV) infusion of the medium-chain fatty acid caprylic acid (CA) with those of the long-chain fatty acid
oleic acid (OA). Contrary to our expectation, six-h HPV infusion of 14 μg/min (50 nmol/min) OA robustly inhibited feeding, whereas infusion of
22 or 220 μg/min (150 and 1500 nmol/min) CA failed to have any effect on feeding. Only a much larger dose of CA, 1100 μg/min (7500 nmol/
min) inhibited feeding similarly to 14 μg/min OA. The increased feeding-inhibitory potency of OA did not appear to be due to differences in
stimulation of hepatic fatty acid oxidation because equimolar (50 nmol/min) doses of OA (14 μg/min) and CA (7 μg/min) did not differentially
affect post-infusion levels of β-hydroxybutyrate. Stress, inflammation, acute hepatotoxicity or oxidative stress also do not appear to account for
the increased feeding-inhibitory potency of HPV OA because plasma concentrations of the stress hormones corticosterone and epinephrine, the
pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-α, the liver enzymes γ-glutamyl transferase and alanine aminotransferase and
as well as hepatic levels of malondialdehyde and glutathione were all similar after HPV infusion of saline or of 50 nmol/min OA or CA.
© 2006 Elsevier Inc. All rights reserved.Keywords: Satiety; Liver; Fatty acid oxidation; Long-chain fatty acids; Medium-chain fatty acids1. Introduction
Several studies in both animals [5,8,12,17] and humans
[26,31,32] suggest that medium-chain triglycerides (MCT)
enhance satiety and decrease food intake more than long-chain
triglycerides (LCT). The reason for this difference is unknown,
but the differences in post-absorptive handling of MCTand LCT
may be important. First, medium-chain fatty acids (MCFA)
derived from digestion of MCT are absorbed directly into the
hepatic portal vein (HPV), whereas long-chain fatty acids
(LCFA) from LCTare packaged into chylomicrons and absorbed
into the lymphatic system [23], thus bypassing the liver. Second,⁎ Corresponding author. Institute of Animal Sciences, ETH Zurich, Schor-
enstr. 16, 8603 Schwerzenbach, Switzerland. Tel.: +41 44 655 7419; fax: +41 44
655 7201.
E-mail address: monika-leonhardt@ethz.ch (M. Leonhardt).
0031-9384/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.physbeh.2006.06.020the transport of MCFA into the mitochondria does not require
carnitine palmitoyltransferase-1, which is the rate-limiting step
of mitochondrial transport of LCFA [33]. Both of these effects
would tend to favor hepatic oxidation of MCFA compared to
LCFA. Consistent with this, oxidation of MCFAwas reported to
increase ketogenesis — an indicator of hepatic fatty acid oxi-
dation (FAO)—more than did the oxidation of LCFA in humans
[32]. Because hepatic FAO is thought to inhibit eating, (for
review see Refs. [15,18]) the more pronounced effect of MCFA
on hepatic FAO could explain the apparently superior satiating
potency of MCT. This reasoning would also suggest that MCFA
would be more satiating than LCFA. Cox et al. [7] and Meyer et
al. [20], however, reported the opposite result: Intra-intestinal
infusions of the MCFA caprylic acid (CA) reduced food intake
less, not more, than isoenergetic intra-intestinal infusion of the
LCFA oleic acid (OA). One potential explanation for this is that
OA elicited more potent pre-absorptive feeding-inhibitory
Fig. 1. Effects of HPV infusion of 14 μg/min OA and equimolar saline on
cumulative food intake in 2 h-food deprived rats re-fed at dark onset. Infusions
began 1 h prior to dark onset and ended 6 h later (dotted lines). Gray background
indicates dark phase. Data are means±SEM intakes of 13 rats tested using a
crossover design. SAL, saline; OA, oleic acid. ⁎Significantly different fromSAL at
3 h and all subsequent time points; Tukey test after significant ANOVA, Pb0.05.
330 U.L. Jambor de Sousa et al. / Physiology & Behavior 89 (2006) 329–334signals than CA [7], and that this difference overshadowed the
stronger post-absorptive feeding-inhibitory signal arising from
hepatic oxidation of CA. We tested this hypothesis in the current
experiments by comparing the effects of HPV infusions of OA
and CA on food intake.
2. Methods
2.1. Animals
Male rats weighing 400–590 g during tests were bred locally
in SPF conditions using Sprague–Dawley founders from Charles
River Germany. For tests, rats were individually housed in wire-
mesh cages with ad libitum access to water and ground rat chow
(No. 3433, Provimi Kliba, Kaiseraugst, Switzerland) with a
metabolizable energy content of 12.4 kJ/g. The colony room was
temperature-controlled (22±2 °C) with a reversed 12:12-h light–
dark cycle. Rats were adapted to these housing conditions and to
daily handling and weighing for at least 8 days before surgery. All
protocols for these experiments were approved by the Veterinary
Office of the Canton of Zurich.
2.2. Surgery
Rats were anesthetized by intraperitioneal injection (1.25 ml/
kg) of 100 mg/kg ketamine (Ketasol-100, Dr. E. Gräub AG,
Bern, Switzerland), 5 mg/kg xylazine (Rompun, Bayer,
Leverkusen, Germany), and 0.05 mg/kg acepromazine (Pre-
quillan, Arovet AG, Zollikon, Switzerland). One or two
intravascular catheters were implanted using a sterile technique,
as described below. For postoperative analgesia rats received
subcutaneously 5 mg/kg/d carprofen (Rimadyl, Dr. E. Gräub
AG) for the following 2 days.
2.2.1. HPV catheters
Catheters and headsets were custom-made from silicon
tubing (ID 0.51 mm, OD 0.94 mm, length 27 cm; Ulrich
Swiss, St. Gallen, Switzerland), a 20-gauge Vacutainer cannula
(Becton–Dickenson, Basel, Switzerland), and polypropylene
surgical mesh (2.5×2.5 cm, Bard mesh, Oberrieden, Switzer-
land), implanted in the ileocolic vein and advanced into the HPV,
exteriorized in the interscapular area, and fitted with caps as
previously described [27]. Silk suture (Silkam, 3/0, Braun,
Melsungen, Germany) and glue (Histoacryl, Braun) were used to
fix the catheter to the ileocolic vein, and resorbable suture (3-0
Vicryl, Ethicon GmbH, Norderstedt, Germany) was used to
close the skin and muscle. During the first postoperative week
the catheters were flushed daily with 0.3 ml 0.9% sterile saline
and filled with 80 μl heparinized saline (100 I.U./ml heparin,
Braun), thereafter every second day.
2.2.2. Jugular vein catheters
Silicon (ID 0.51 mm, OD 0.94 mm, length 10.5 cm) catheters
were implanted into the jugular vein and advanced to the right
atrium using the original method of Steffens [24], modified as
previously described [10], exteriorized 1 cm rostral to the HPV
catheter, and fitted with caps. Catheters were flushed every daywith 0.2 ml 0.9% saline and then filled with 70–100 μl PVP-
heparin (Polyvinylpyrrolidone, Sigma, Buchs, Switzerland).
2.3. Test procedure
About 1 week after surgery, rats were housed individually in
open-topped plexiglass cages (37×21×41 cm) with stainless
steel grid floors. Rats had ad libitum access to water, in sipper
tubes hung outside the cage, and ground chow, which was in food
cups placed under a 39 cm2 hole at the end of a niche in the cage
wall that was 4.6 cm wide, 7 cm deep, and 29.5 cm high, with the
base 5 cm above the cage floor. The cups were mounted on
electronic balances (Mettler PM 3000, Greifensee, Switzerland)
that were interfaced with a computer (Olivetti M 300, Nürnberg,
Germany) in an adjacent room. A custom-designed program
(VZM; Krügel, Munich, Germany) recorded the weights of the
food cups every 30 s, enabling continuous measurement of
spontaneous feeding patterns. In addition, a video system
(Enhanced Observation Kit VSS 2285/OOT, Philips, Zurich,
Switzerland) permitted continuous observation of the rats.
Each day the HPV catheter was attached to a syringe pump
(model A99; Razel, Stamford, CT, USA) mounted above the cage
via a segment of Tygon tubing (0.76 mm ID, 1.22 mmOD; Portex,
Hythe, Kent; UK) sheathed with a stainless steel spring and
connected to a swivel joint fixed ∼ 45 cm above the cage floor,
which allowed the rat to move freely. The infusion pumps were
remotely controlled from the adjacent room. Six-hour infusions
(22μl/min) began 1 h prior to dark onset. At the end of the infusions
the catheter was detached and flushed, and the headset was capped.
Rats were adapted to this procedure several times before tests.
The patency of the hepatic portal vein catheters was checked
at sacrifice of the rats. We verified whether the tip of the catheter
Table 1
















SAL 22.6±0.8 8.3±0.4 2.8±0.1 13.9±1.2 80.0±1.2
CA 22.5±0.7 8.5±0.5 2.7±0.1 14.4±1.1 74.7±5.0
1100 μg/min (n=12)
SAL 19.3±0.9 8.3±0.6 2.4±0.1 11.4±1.0 79.0±5.7
CA 14.7±1.3⁎ 6.8±0.7 2.2±0.1 12.4±1.3 95.5±8.8
14 μg/min (n=13)
SAL 23.1±0.8 7.2±0.5 3.2±0.2 10.7±0.7 90.8±7.2
OA 17.2±1.5⁎⁎ 5.8±0.5⁎ 3.0±0.2 11.4±1.0 110.2±10.9
Data are means±SEM; FI, food intake; IMI, inter meal interval; SAL, saline.
⁎Pb0.05; ⁎⁎Pb0.01.
Fig. 2. Effects of HPV infusions of 220 μg/min (A) and 1100 μg/min (B) CA and
equimolar saline on cumulative food intake in 2 h-food deprived rats re-fed at
dark onset. Infusions began 1 h prior to dark onset and ended 6 h later (dotted
lines). Gray background indicates dark phase. Data are means±SEM intakes of
12 rats tested using a crossover design. SAL, saline; CA, caprylic acid.
⁎Significantly different from SAL at 3 h and all subsequent time points; Tukey
test after significant ANOVA, Pb0.05.
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open and did not leak. Only rats that met these criteria were
included in the data analysis.
2.4. Experimental designs
2.4.1. Experiment 1: effect of HPV OA infusion on food intake
The effects of HPV infusions of OA (sodium oleate, Sigma;
OA equivalents below) on feeding were tested in 13 rats with
HPV catheters. Rats were food deprived for 2 h, and food was
returned at the beginning of the dark phase, 1 h after the infusion
started. Six-hour infusions of OA (50 nmol/min, 14 μg/min), or
equimolar, equal pH saline were tested using a crossover design,
with at least 2 days of ad libitum feeding between trials. Sterile
infusion solutions 2.3 mmol/l sodium oleate (corresponding to
0.65 g/l OA) were prepared daily by heating 15 min at 56 °C,
adjusting the pH to 7.4, and filtering (Nalgene 0.2 μm, Nalge
Nunc International, Rochester, NY, USA).
2.4.2. Experiment 2: Effects of HPV CA infusion on food intake
and plasma metabolites
The effects of HPV infusions of 3 different doses of CA
(sodium caprylate, Sigma; CA equivalents below) on feeding
and plasma metabolites were tested in a new group of 12 rats
with HPV and jugular vein catheters. As in Experiment 1, rats
were food deprived for 2 h, and food was returned at the
beginning of the dark phase, 1 h after the infusion started. Six-
hour infusions of CA (150, 1500 and 7500 nmol/min; 22, 220
and 1100 μg/min, respectively) or equimolar, equal pH saline
were tested using a crossover design, with at least 2 days of ad
libitum feeding between trials. Sterile infusion solutions of
7mmol/l (1.0 g/l), 70mmol/l (10.1 g/l) and 350mmol/l (50.5 g/l)
CAwere prepared daily by heating 5 min at 45 °C, adjusting the
pH to 7.4, and filtering (Nalgene 0.2 μm, Nalge Nunc
International, Rochester, NY, USA).
At the end of the infusion, the jugular catheters were attached
and a 900-μl blood sample was taken. An equal volume of
saline was then infused, and the catheter was detached and
refilled with PVP-heparin. Blood was mixed with NaF (3 mg/ml
whole blood), stored on ice during the experiment, and
centrifuged for 8 min at 8000 rpm at 4 °C immediately after-wards. Plasma was aliquoted and stored at − 20 °C. Glucose,
free fatty acids (FFA), and β-hydroxybutyrate (BHB) were
analyzed as previously described [16].
2.4.3. Experiment 3: effects of HPV OA and CA infusions on
plasmametabolites, stress hormones, liver enzymes and cytokines
Blood samples were taken in a situation that was similar to the
feeding tests, i.e., during a crossover test of OA and CA (50 nmol/
min), with at least 2 days between consecutive experiments, in
food-deprived rats (n=8 new rats, with HPV and jugular vein
catheters). Two hours before lights out, foodwas removed and the
Fig. 3. Effects of HPV infusion of 14 μg/min OA, 1100 μg/min CA and saline
(equimolar to CA) on hepatic lipid peroxidation as determined by malondialdehyde
(MDA)andglutathione (GSH) levels at the endof the infusion.Data aremeans±SEM.
SAL, saline; OA, oleic acid; CA, caprylic acid. ⁎Significantly different from SAL,
Kruskal–Wallis test followed by Mann–WhitneyU-test, Pb0.05.
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700-μl blood sample was withdrawn and 700-μl saline was
injected. The jugular vein catheters were then detached and filled
with PVP-heparin. Thereafter, the HPV catheters were attached
and 75min before lights out, a 3.0–3.2 g chow pellet was offered,
and 15 min later the remaining food was removed, intake was
verified to be at least 2.8 g, and 6 h infusions of OA or CA began.
Rats had no access to food during infusions. At the end of the
infusion, the jugular catheters were attached and 30 min later a
700-μl blood sample was taken. An equal volume of saline was
infused afterwards, and the jugular vein catheter was then
detached and refilled with PVP-heparin. Blood was mixed with
EDTA (1.8 mg/ml whole blood), stored on ice during the
experiment, and then centrifuged for 8 min at 8000 rpm at 4 °C.
Plasma aliquots were stored at −70 °C. Corticosterone was
analyzed by RIA (Linco Research, St. Charles, MI, USA),
epinephrine was measured by HPLC with electrochemical
detection [22], the pro-inflammatory cytokines tumor necrosis
factor-α (TNF-α) and interleukin-6 (IL-6) were measured by
immunoassay (Linco Research) in a Luminex100 (Linco Re-
search), and the other assays were performed as previously
described [16].
2.4.4. Experiment 4: effects of HPV OA and CA infusions on
hepatic malondialdehyde (MDA) and glutathione (GSH) levels
Rats (n=13, previously used in experiment 3) were divided in
three groups with 3 or 4 rats per group. Two hours before lights out
food was removed and 1 h later HPV catheters were attached. A
3.0–3.2 g chow pellet was offered, and 15 min later the remaining
food was removed, intake was verified to be at least 2.8 g, and 6 h
infusions of OA (50 nmol/min, 14 μg/min), CA (7500 nmol/min,
1100μg/min) or SAL (equimolar toCA) began. Rats had no access
to food during infusions. At the end of the infusion, the HPVTable 2
Plasma metabolites, stress hormones, liver enzymes and cytokines before (basal)
and after hepatical portal vein infusion (6 h) of caprylic acid (CA) and oleic acid
(OA)
CA (7.2 μg/min) OA (14 μg/min)
50 nmol/min 50 nmol/min
Basal 6 h Basal 6 h
Metabolites
Glu (mmol/l)⁎ 8.1±0.1 6.7±0.2 8.3±0.2 6.6±0.2
FFA (μmol/l)⁎ 198±22 662±55 214±18 664±78
BHB (μmol/l)⁎ 43±9 448±48 44±13 485±56
Hormones
Cort (μg/l)⁎ 73±6 107±11 64±9 115±15
Epi (pg/ml)⁎ 23±10 61±10 20±7 48±10
Liver enzymes
ALT (U/l) 40±3 42±3
γ-GT (U/l) 1.1±0.2 0.9±0.1
Cytokines
TNF-α (pg/ml) 14±6 14±9
IL-6 (pg/ml) 861±398 1072±415
Glu, glucose; FFA, free fatty acids; BHB, β-hydroxybutyrate; Cort, corticoste-
rone; Epi, epinephrine; Alt, alanine amino-transferase; γ-GT, γ-glutamyl
transferase; TNF-α, tumor necrosis factor-α, IL-6, interleukin-6.
Data are means±SEM, n=8.
⁎6-h value significantly different from basal value, Pb0.05.catheters were detached and rats were anesthetized with ether. A
liver sample was taken and homogenized in 600 μl/100 mg tissue
of PBS (pH 7.4) containing 1% CHAPS (Pierce, Rockford, IL,
USA). To analyze MDA, the homogenate containing 5 mM
butylated hydroxytoluene in 20 mM Tris was centrifuged to
remove cellular debris, purified using the methanesulfonic acid
solvent extraction procedure, and absorbance was measured at
586 nm [1]. GSH levels were measured using a method based on
the formation of a chromophoric product resulting from the
reaction of 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTNB, Sigma)
and GSH (Calbiochem, San Diego, CA, USA) [29].
2.5. Data collection and analysis
Mealswere defined asweight changes≥0.3 g, lasting≥1min,
and separated by≥15 min from other weight changes [27]. Meal
duration was the time from the first to the last weight change in a
single meal, and the inter-meal interval (IMI) was the time from
the last weight change in a meal to the first change in the next
meal. Data are expressed as means±SEM. Cumulative food
intakes (experiments 1 and 2), plasma metabolites and stress
hormones (experiment 3) were analyzed by repeated-measures
analysis of variance (ANOVA) with infusion and time as factors,
and post hoc comparisons between means were done with
Tukey's HSD test. Meal pattern (experiments 1 and 2) and the
other plasma parameters (experiments 2 and 3) were analyzed
with paired t-tests. In Experiment 4, the data did not meet the
requirements for ANOVA and were analyzed by a Kruskal–
Wallis test followed byMann–WhitneyU-test.Minimum level of
significance was Pb0.05.
3. Results
3.1. Experiment 1: effect of HPV OA infusion on food intake
Six hHPVinfusions of 50 nmol/min (14 μg/min) OA reduced
cumulative food intake from 3 h after the start of infusions until
333U.L. Jambor de Sousa et al. / Physiology & Behavior 89 (2006) 329–334the end of the test (Fig. 1; main effect of drug, F(1, 276)=16.4;
Pb0.01; interaction effect of drug and time, F(23, 276)=3.5;
Pb0.0001). This reduction was due mainly to a significant
decrease in the number of meals during the dark phase without a
significant change in nocturnal meal size (Table 1).
3.2. Experiment 2: effects of HPV CA infusion on food intake
and plasma metabolites
Six h HPV infusions of 150 (22 μg/min) or 1500 nmol/min
(220 μg/min) CA did not affect either cumulative food intake
(Fig. 2A) or meal patterns (Table 1; data for lower CA dose not
shown). HPV infusion of 7500 nmol/min (1100 μg/min) CA
significantly reduced cumulative food intake (Fig. 2B) from 3 h
after the start of infusions until the end of the test (main effect of
drug, F(1, 242)=10.1; Pb0.01; interaction effect of drug and
time, (F(22, 242)=9.4; Pb0.0001). No reliable changes in meal
size or meal number were detected (Table 1).
HPV CA infusion did not significantly affect the plasma con-
centration of any of the parameters examined. Following infusion
of 1100 μg/min CA, plasma glucose levels were 7.7±0.2 mmol/
l (SAL) and 7.6±0.2 mmol/l (CA), PN0.10, BHB levels were
30±7 μmol/l and 38±8 μmol/l, PN0.10, and FFA levels were
0.13±0.01 mmol/l and 0.30±0.09 mmol/l, t(9)=1.873; P=0.09.
3.3. Experiment 3: effects of equimolar HPV OA and CA
infusions on plasma metabolites, stress hormones, liver enzymes
and cytokines
The 6 h values of all the metabolites (glucose, FFA and
BHB) and stress hormones (corticosterone and epinephrine)
examined differed significantly from the basal values (Table 2),
but there were no significant main effects of OA and CA
infusions and no significant time-infusion interactions. Post-
infusion plasma levels of the pro-inflammatory cytokines TNF-
α and IL-6 and the liver enzymes alanine aminotransferase
(ALT) and γ-glutamyl transferase (γ-GT) also did not differ
significantly between the two groups (Table 2).
3.4. Experiment 4: effects of HPV OA and CA infusions on
hepatic MDA and GSH levels
Neither OA nor CA infusion increased the production of
reactive oxygen species (ROS) as assessed by hepatic MDA or
GSH levels (Fig. 3). Indeed, MDA levels were significantly
reduced after OA infusion.
4. Discussion
Extensive evidence indicates that hepatic FAO can control
food intake [11,15,18]. This study was designed to test the
hypothesis that, due to the more rapid hepatic oxidation ofMCFA
than LCFA,HPVinfusion of theMCFACAwould inhibit feeding
more potently than HPV infusion of comparable amounts of the
LCFA OA. The results disconfirmed this hypothesis. Under our
conditions, HPV infusion of 50 nmol/min (14 μg/min) OA
produced a robust inhibition of feeding, whereas HPV infusion of150 and 1500 nmol/min (22 and 220 μg/min) CA failed to have
any effect on feeding. Feeding-inhibitory effects similar to those
of 50 nmol/min (14 μg/min) OA were observed after HPV
infusion of 7500 nmol/min (1100 μg/min) CA, i.e., 150 times the
molar dose and 80-times the weight dose. Why HPV OAwas so
much more potent than HPV CA is not clear. Grekin et al. [13]
calculated that HPV infusion of 250 nmol/min OA increased
hepatic OA delivery by only 12% and total fatty acid delivery by
2%. Thus, the 5-times smaller OA dose we used seems very
unlikely to increase hepatic FAOmore than the larger dose of CA.
Contrary to our expectation, plasma BHB levels were not
significantly increased after the larger dose of CA in Experiment
2. At first glance this suggests that even this CA dose did not
increase hepatic FAO. Yet, plasma BHB is only an indirect
measure of hepatic FAO, and the failure to detect an increase in
plasma BHB levels is probably due to the fact that the rats had
access to chow throughout this test, which rapidly decreases
ketogenesis and, hence, the ratio of BHB to total fatty acids in the
plasma [34]. Indeed, we recently demonstrated that HPV CA
attenuated the drop in plasmaBHB levelswhen rats where offered
a 4-g test meal after 18 h of food deprivation [14], and in
Experiment 3, when the rats were given only a 3 g testmeal before
the onset of infusions, plasmaBHB at the end of the infusions was
similarly increased by 7 μg/min CA and 14 μg/min OA. All in all,
our data do not support the hypothesis that the rate of hepatic FAO
determines the differential feeding-inhibitory potencies of
circulating CA and OA.
Our feeding data are qualitatively similar to reports that intra-
intestinal infusions of OA inhibited feeding more than similar
doses of CA [7,20,35]. Furthermore, as in our study, intra-
intestinal infusion of OA decreased food intake by reducing the
number of meals without affecting meal size [7]. As a substantial
part of the inhibition of feeding produced by intra-intestinal fat
infusions is based on pre-absorptive signaling mechanisms
[2,4,25,30,36], however, the relevance of these data to the effects
of post-absorptive nutrient infusions is uncertain.
The different feeding-inhibitory potencies of OA and CA
may be related to differential effects on hepatic vagal afferent
activity. Vagal afferent signaling apparently mediates much of
the control of food intake by lipids in the small intestine [6,7,35]
as well as by hepatic lipid metabolism [18]. Vagal receptors
with different sensitivity to LCFA and MCFA have been
identified in the small intestine [19], and HPV infusion of the
LCFA linoleic acid increased hepatic vagal afferent activity
more than the same amount of CA [28].
Finally, although administration of large doses of LCFA and
MCFA can have nonspecific or toxic effects that could inhibit
feeding differentially, such effects did not seem to occur here. For
example, intra-duodenal infusions of 7.2 or 14.4 mg/min sodium
OA for 10min, but not equicaloric doses of sodiumCA, increased
intestinal lactate dehydrogenase activity, which is a marker for
cell death, and produced a conditioned taste aversion [21].
Similarly, HPV infusion of 42 μg/min OA for 24 h markedly
increased plasma concentrations of the stress hormone cortico-
sterone [3] and the liver enzyme ALT, which is a marker for
hepatocyte damage. In contrast, in our study the effects of
6 h HPV infusion of 14 μg/min OA on plasma corticosterone and
334 U.L. Jambor de Sousa et al. / Physiology & Behavior 89 (2006) 329–334epinephrine did not differ from HPV infusion of equimolar CA.
The significantly higher 6 h values in comparison to the basal
valuesmight be related to the fasting because rats had no access to
food during the infusion. Furthermore, HPV OA infusion did not
increase plasma levels of the liver enzymes ALT and γ-GT or of
the pro-inflammatory cytokines TNFα and IL-6 in comparison to
equimolar HPV CA. Finally, neither HPV OA nor CA induced
oxidative stress in liver cells as assessed by hepatic concentrations
of MDA or GSH. Indeed, HPV OA significantly reduced hepatic
MDA levels, perhaps because moderate amounts of LCFA ap-
parently can enhance ROS degradation [9].
In conclusion, the present data provide evidence that HPV
infusions of OA in doses that fail to produce overt signs of
toxicity inhibit feeding markedly more than HPV infusions of
CA. This did not appear to be due to differential effects on
hepatic FAO. The mechanisms involved remain unclear. Given
the importance of dietary fat in the control of food intake and
bodyweight, the apparent paradox between one body of research
suggesting that MCT ingestion reduces food intake more than
LCTand another body of research indicating that intra-intestinal
and HPV infusion of LCFA reduces food intake more than
infusion of MCFA deserves further research.
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